logo
PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

Globe and Mail21-05-2025
MONTREAL, May 21, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. ('PyroGenesis') (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces today further to its news release dated May 15, 2025, and today's press release from the Company's client HPQ Silicon Inc. ('HPQ'), independent analysis of material produced during the latest phase of system testing of the Fumed Silica Reactor (the 'FSR') is in fact fumed silica. PyroGenesis is engaged to develop the Fumed Silica Reactor by HPQ Silica Polvere Inc. ('Polvere'), a subsidiary of HPQ.
As previously announced, the new PyroGenesis designed FSR pilot plant has progressed through several important stages. After successfully proving out the underlying assumptions using lab scale tests, PyroGenesis is now testing the assumptions at pilot plant scale, with the current focus on validating equipment scale-up from lab to pilot plant scale and replicating the lab-scale fumed silica product quality.
PyroGenesis recently announced that (i) an important milestone of producing and collecting powder in the product recovery unit known as the 'baghouse' had been achieved, and (ii) samples had been sent to an independent laboratory to confirm that (a) the powder collected was fumed silica, and (b) what was collected was what was expected, and that any impurities that are observed were not only anticipated but are in a state that was expected and which can be removed.
The announcement today confirms that an independent analysis of the powder reflects that:
(1) the powder collected from the baghouse is in fact fumed silica,
(2) any impurities observed were not only anticipated but are in a state that was expected and which can be removed, and
(3) the amount produced was greater than anticipated and as such bodes well for the ultimate economics of the project.
Figure 1. TEM images of fumed silica nanoparticles, (a) Lab-Scale Silica Polvere collected from inside the Reactor (b1-b2) Pilot-Scale Silica Polvere collected from the Baghouse and (c1) Evonik Commercial Grade Aerosil 90, (c2) Evonik Commercial Grade Aerosil 150, (c3) Evonik Commercial Grade Aerosil 200
In a side-by-side comparison, the PyroGenesis material appears well aligned with the microstructure and complexity of mid to high surface area of commercial grade fumed silica produced by Evonik Corporation, typically in the range of 150 to 200 m²/g.
The balance of the pilot plant program will now be focused on two primary objectives:
a) first, to focus on enhancing product purity by perfecting powder morphology and viscosity, and
b) second, to focus on delivering the production target goal of 50 tonnes per year (TPY).
In parallel, the FSR pilot plant will undergo a series of optimization tests, which aim to:
Improve process control and parameter stability,
Increase silica conversion efficiency and yield, and
Increase product surface areas.
These efforts will provide invaluable information required for scale-up plans and equipment modifications required to make the system commercially viable. Together, the results of the characterization and optimization phases will essentially determine market fit.
'Today's announcement is a welcomed milestone which has increased the probability of success, but we must remember that until we have proven out every step, there is no guarantee that success will be the result,' said P. Peter Pascali, President and CEO of PyroGenesis, 'Having said that we are very pleased with the results of this analysis, as it confirms our theoretical expectations at a key juncture in the overall project.'
Fumed silica is one of the most widely used industrial materials, and can be found in thousands of products we use every day, including personal care, cosmetics, toothpaste, pet litter, powdered food, milkshakes, instant coffee, pharmaceuticals, agriculture (food & feed), adhesives, paints, inks, photocopy toner, sealants, fiber optic cables, thermal insulation, construction materials, and batteries, just to name a few. It is often used in these products as a thickening/anti-caking agent, used to stabilize and improve the texture and consistency of the end-product.
PyroGenesis' involvement in developing fumed silica from quartz is part of its three-vertical solution ecosystem that aligns with economic drivers that are key to global heavy industry. Fumed powders are part of PyroGenesis' Commodity Security and Optimization vertical, where the development of advanced material production techniques, and the use of technology such as plasma to recover viable metals, chemicals, and minerals from industrial waste, helps to maximize raw materials and improve the availability of critical minerals. The Company's other verticals are Energy Transition and Emission Reduction and Waste Remediation.
About PyroGenesis Inc.
PyroGenesis, a high-tech company, is a proud leader in the design, development, manufacture and commercialization of advanced plasma processes and sustainable solutions which reduce greenhouse gases (GHG) and are economically attractive alternatives to conventional 'dirty' processes. PyroGenesis has created proprietary, patented and advanced plasma technologies that are being vetted and adopted by multiple multibillion dollar industry leaders in four massive markets: iron ore pelletization, aluminum, waste management, and additive manufacturing. With a team of experienced engineers, scientists and technicians working out of its Montreal office, and its 3,800 m 2 and 2,940 m 2 manufacturing facilities, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The operations are ISO 9001:2015 and AS9100D certified, having been ISO certified since 1997. PyroGenesis' shares are publicly traded on the TSX in Canada (TSX: PYR), the OTCQX in the US (OTCQX: PYRGF), and the Frankfurt Stock Exchange in Germany (FRA: 8PY1).
Cautionary and Forward-Looking Statements
This press release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'targets', 'expects' or 'does not expect', 'is expected', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management's current beliefs, expectations, estimates and projections regarding future events and operating performance.
Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under 'Risk Factors' in PyroGenesis' latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis' profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws.
Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cabinet to meet Tuesday as Trump says 35% tariff letter is ‘the deal'
Cabinet to meet Tuesday as Trump says 35% tariff letter is ‘the deal'

Toronto Star

time7 minutes ago

  • Toronto Star

Cabinet to meet Tuesday as Trump says 35% tariff letter is ‘the deal'

U.S. President Donald Trump said on Monday that the letters he sent to Prime Minister Mark Carney and other leaders about new tariff rates are 'the deals', as Carney prepares to meet with his cabinet on tariffs and the trade negotiations. Trump appeared to be losing patience with his administration's efforts to make trade deals with nations around the world. The president has been sending letters to trading partners, including Canada, threatening to impose higher tariff rates on Aug. 1. The letter addressed to Carney last week said Canada would be hit with 35 per cent tariffs but the White House later said it would not include goods compliant with the Canada-U.S.-Mexico Agreement on trade.

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.

Globe and Mail

time13 minutes ago

  • Globe and Mail

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own as well as a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash (payable following the first commercial sale of VG-3927 if achieved within a specific period). KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

Global Artificial Intelligence in Oncology Market Size to Hit USD 2,145.1 Million by 2025, grow at a CAGR of 33.7%
Global Artificial Intelligence in Oncology Market Size to Hit USD 2,145.1 Million by 2025, grow at a CAGR of 33.7%

Globe and Mail

time13 minutes ago

  • Globe and Mail

Global Artificial Intelligence in Oncology Market Size to Hit USD 2,145.1 Million by 2025, grow at a CAGR of 33.7%

Artificial intelligence (AI) is playing an increasingly important role in oncology. There are various types of AI products that are helping in cancer screening, diagnosis, treatment, and drug development. One of the major products is an AI-assisted cancer screening tool. These tools use deep learning algorithms that have been trained on huge databases of medical images. Global Artificial Intelligence in Oncology Market Key Takeaways According to Coherent Market Insights (CMI), the global artificial intelligence in oncology market size is expected to grow more than 7.6X, from USD 2,145.1 Mn in 2025 to USD 16,382 Mn by 2032, exhibiting a robust CAGR of 33.7%. Based on component, software/platform segment is anticipated to account for a prominent market share of 64.2% in 2025. North America is expected to retain its dominance, accounting for more than one-third of the global artificial intelligence in oncology market share in 2025. Europe is projected to remain the second-leading market for AI-powered oncology companies. As per Coherent Market Insights' new global artificial intelligence in oncology market analysis, Asia Pacific is poised to witness fastest growth throughout the assessment period. Increasing Cancer Prevalence Spurring Market Growth Coherent Market Insights' latest global artificial intelligence in oncology market research report highlights key factors driving market growth. One such prominent growth factor is the rising incidence of cancer. The IARC's Global Cancer Observatory projects that annual new cancer cases will surpass 35 million by 2050. This sharp rise in cancer incidence is anticipated to drive demand for artificial intelligence in oncology. Artificial intelligence is revolutionizing oncology by enhancing cancer detection, treatment planning, and drug discovery. Therefore, growing cancer burden is poised to play a crucial role in driving adoption of AI-based oncology solutions over the forecast period. High Implementation Costs and Data Privacy Concerns Restraining Market Growth The global artificial intelligence in oncology market outlook indicates strong future growth. However, high implementation costs and data security concerns are limiting market growth to some extent. Integrating AI technologies into oncology workflows requires significant investment in hardware and software. This deters small and mid-sized healthcare companies from opting for these technologies, thereby reducing global artificial intelligence in oncology market demand. AI systems require access to large amounts of patient data, raising concerns about cybersecurity risks as well as potential misuse. This may also negatively impact the global artificial intelligence in oncology market growth during the projection period. Get Instant Access! Purchase Research Report and Receive a 25% Discount: Technological Advancements in AI Creating New Growth Prospects for the Market Ongoing innovations in deep learning, computer vision, and natural language processing (NLP) are significantly enhancing AI applications in image analysis, drug discovery, and prognosis prediction. Such breakthroughs are expected to unlock new revenue-generation streams for industry players. Advanced AI technologies are being increasingly integrated with imaging modalities like MRI and PET scans. This integration enables automated detection of anomalies, enhances diagnostic accuracy, and reduces human error. Emerging Global Artificial Intelligence in Oncology Market Trends Rising demand for precision medicine is a key growth-shaping trend in the market. Precision oncology requires analyzing large datasets, including genomics and biomarkers. This is where AI steps in, processing huge data and enabling creation of individualized therapies. Expanding use of artificial intelligence in radiology and pathology is expected to boost the market. AI technologies are being increasingly used for tumor detection, segmentation, and classification through radiological and histopathological images. This is due to their ability to improve speed and consistency as well as reduce diagnostic errors. Increasing adoption of AI in drug discovery and development is positively impacting the global artificial intelligence in oncology market value. This advanced technology is revolutionizing drug discovery by rapidly analyzing large datasets to identify potential drug candidates as well as predict their efficacy and toxicity. Growing adoption of cloud-based AI solutions is significantly contributing to the expansion of the global artificial intelligence in oncology market. These solutions are increasingly favored for their cost-efficiency, scalability, and ability to provide seamless remote access to data and tools. Analyst's View ' The global artificial intelligence in oncology market is set for rapid expansion, owing to growing prevalence of cancer, rising adoption of precision medicine, and technological advancements in AI technologies,' said senior analyst Komal Dighe. Current Events and Their Impact on the Global Artificial Intelligence in Oncology Market Event Description and Impact FDA Clears First GenAI-Powered Diagnostic Tool for Breast Cancer Detection (2025) Description: The U.S. FDA approved a GenAI-based diagnostic platform by PathIntel, capable of identifying breast cancer subtypes with high accuracy using real-world data. Impact: Such approvals signal growing regulatory acceptance of generative AI in oncology. Tempus Collaborated with Boehringer to Accelerate AI Usage in Oncology Description: In May 2025, Tempus entered a multi-year strategic collaboration with Boehringer Ingelheim to apply its AI-driven oncology insights toward cancer‑focused therapeutic discovery and biomarker development Impact: This will likely boost growth of the AI in oncology market. Japan's MHLW Updates Reimbursement Guidelines for AI Diagnostics Description: Japanese Ministry of Health, Labour and Welfare (MHLW) has approved reimbursement for certain AI-enhanced imaging diagnostics Impact: Such initiatives will increase commercial viability and adoption of AI oncology tools in Asia-Pacific, spurring more localized R&D and product launches. Competitor Insights Key companies listed in the global artificial intelligence in oncology market report: - IBM Corporation - Intel Corporation - Azra AI - NVIDIA Corporation - Siemens Healthineers AG - GE HealthCare - Digital Diagnostics Inc. - ConcertAI - PathAI - Median Technologies - Microsoft - Babylon - Zebra Medical Vision Key Developments In June 2025, launched a new strategic alliance with Novartis to accelerate timely diagnosis and deliver AI-powered precision care for cancer patients. Through this collaboration, will focus on developing AI-powered workflows for breast and prostate cancer. In November 2024, PathAI unveiled PathExplore Fibrosis. This new AI-powered tool is designed to revolutionize collagen, fibrosis, and fiber quantification directly from whole-slide images. In January 2024, PathAI launched six additional oncology indications for PathExplore, expanding the AI-driven pathology panel to cover ovarian, bladder, liver, small cell lung, lymphoma, and head & neck cancers. Global Artificial Intelligence in Oncology Market Segmentation: By Component Software/Platform Hardware Services By Cancer Type Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Brain Tumor Others By Treatment Type Chemotherapy Radiotherapy Immunotherapy Others By End User: Hospitals & Clinics Diagnostic Centers Biopharmaceutical Companies Others By Region North America Latin America Europe Asia Pacific Middle East Africa About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store